The CLK inhibitor TG693 (6) modulates the mutated exon 31 of the dystrophin gene in mice, and might be a suitable starting point for the development of therapeutics against the Duchenne muscular dystrophy (DMD). The gene discussed is CLK1; the disease is Duchenne muscular dystrophy.